Summary
Abbott Laboratories reported solid financial performance for the second quarter and first half of 2009, demonstrating resilience amidst challenging economic conditions. Net sales saw a modest increase of 2.5% for the quarter and 0.9% for the first six months, with organic growth partially masked by a stronger U.S. dollar. The company successfully integrated the acquisition of Advanced Medical Optics, Inc. (AMO) and also made significant progress in resolving litigation, notably a $400 million settlement with Medtronic. Operating earnings showed strength, increasing significantly in the second quarter due to a favorable "Other (income) expense, net" item related to the derecognition of a contingent liability from the TAP joint venture conclusion. Despite ongoing patent litigation, particularly concerning Humira, Abbott maintains confidence in its legal positions. The company also continued its share repurchase program and dividend payments, underscoring a commitment to shareholder returns.
Financial Highlights
55 data points| Revenue | $7.49B |
| Cost of Revenue | $3.13B |
| Gross Profit | $4.37B |
| SG&A Expenses | $2.02B |
| Operating Expenses | $5.82B |
| Operating Income | $1.67B |
| Interest Expense | $136.97M |
| Net Income | $1.29B |
| EPS (Basic) | $0.83 |
| EPS (Diluted) | $0.83 |
| Shares Outstanding (Basic) | 1.55B |
| Shares Outstanding (Diluted) | 1.55B |
Key Highlights
- 1Net sales for the second quarter of 2009 increased to $7.5 billion, a 2.5% rise compared to the prior year, driven by strong performance in the Vascular Products segment and the inclusion of results from the newly acquired Advanced Medical Optics (AMO).
- 2Diluted earnings per share (EPS) were $0.83 for the second quarter of 2009, a slight decrease from $0.85 in the prior year, impacted by various factors including the settlement of a contingent liability related to the TAP joint venture which significantly boosted operating earnings but was offset by other factors.
- 3Abbott completed the acquisition of Advanced Medical Optics (AMO) for approximately $1.4 billion in February 2009, significantly expanding its presence in the vision care market. This acquisition contributed to a substantial increase in Goodwill and Intangible Assets.
- 4The company announced a $400 million settlement with Medtronic in July 2009, resolving all outstanding intellectual property litigation related to vascular products. This settlement will be recognized in the third quarter of 2009.
- 5Operating earnings increased substantially in the second quarter of 2009 to $1.67 billion, up from $1.41 billion in the prior year, largely due to a $797 million gain recognized from the derecognition of a contingent liability related to the conclusion of the TAP Pharmaceutical Products Inc. joint venture.
- 6Despite a jury verdict of $1.67 billion in damages in a patent infringement case concerning Humira, Abbott stated it is confident in its legal position and plans to appeal the decision, with no reserves recorded for this case.
- 7Abbott continued to return capital to shareholders, declaring a cash dividend of $0.40 per common share for the second quarter, an increase from $0.36 in the prior year, and repurchased approximately $800 million of its common shares in the first six months of 2009.